Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

Market Cap	181.63B
Revenue (ttm)	80.13B
Net Income (ttm)	25.28B
Shares Out	886.45M
EPS (ttm)	28.52
PE Ratio	7.58
Forward PE	n/a
Dividend	12.00 (5.86%)
Ex-Dividend Date	Nov 17, 2025

Volume	292,283
Average Volume	370,855
Open	204.00
Previous Close	203.60
Day's Range	203.60 - 205.60
52-Week Range	198.90 - 234.10
Beta	0.10
RSI	38.11
Earnings Date	Jan 29, 2026

About DSE:SQURPHARMA

Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, anthelmintics, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, antioxid...

• Industry: Pharmaceutical Preparations
• Founded: 1958
• Employees: 12,453
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SQURPHARMA

Financial Performance

In 2025, DSE:SQURPHARMA's revenue was 76.29 billion, an increase of 8.83% compared to the previous year's 70.10 billion. Earnings were 23.97 billion, an increase of 14.54%.